MCM
LCTX icon

MAI Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

MAI Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Sell
14,394
-1,485
-9% -$2.05K ﹤0.01% 2061
2026
Q1 		$25.1K Sell
15,879
-742
-4% -$1.25K ﹤0.01% 2659
2025
Q4 		$27.8K Sell
16,621
-1,796
-10% -$3.11K ﹤0.01% 2343
2025
Q3 		$31.1K Sell
18,417
-637
-3% -$754 ﹤0.01% 2186
2025
Q2 		$17.3K Sell
19,054
-45,337
-70% -$26.9K ﹤0.01% 2418
2025
Q1 		$29.1K Sell
64,391
-593,288
-90% -$348K ﹤0.01% 2021
2024
Q4 		$330K Sell
657,679
-1,017,000
-61% -$747K ﹤0.01% 965
2024
Q3 		$1.52M Buy
1,674,679
+35,907
+2% +$33.3K 0.01% 456
2024
Q2 		$1.63M Buy
1,638,772
+147,910
+10% +$163K 0.02% 458
2024
Q1 		$2.21M Buy
1,490,862
+687,017
+85% +$779K 0.02% 385
2023
Q4 		$876K Sell
803,845
-150,843
-16% -$165K 0.01% 501
2023
Q3 		$1.13M Buy
954,688
+3,110
+0.3% +$4.23K 0.02% 408
2023
Q2 		$1.34M Buy
951,578
+526,463
+124% +$728K 0.02% 374
2023
Q1 		$638K Sell
425,115
-31,702
-7% -$44.3K 0.01% 558
2022
Q4 		$534K Sell
456,817
-65,053
-12% -$82K 0.01% 597
2022
Q3 		$590K Buy
521,870
+274,135
+111% +$403K 0.01% 506
2022
Q2 		$391K Buy
+247,735
New +$327K 0.01% 619

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MAI Capital Management's LCTX Position: Q2 2026 in Review

MAI Capital Management reduced its Lineage Cell Therapeutics (LCTX) stake by 9.4% in Q2 2026, selling an estimated $2.05K and leaving 14,394 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2061.

MAI Capital Management first reported a position in LCTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $2.21M in Q1 2024. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • MAI Capital Management held 14,394 shares of Lineage Cell Therapeutics worth $18.9K as of Q2 2026.
  • MAI Capital Management sold 1,485 Lineage Cell Therapeutics shares in Q2 2026, an estimated $2.05K.
  • Lineage Cell Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #2061 holding.
  • MAI Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • MAI Capital Management's Lineage Cell Therapeutics position peaked at $2.21M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.